Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              No Association Between Decreases in Serum Immunoglobulin (Ig) Levels Below Lower Limit of Normal (LLN) and Serious Infections (SI) with Long-term Ublituximab (UBL) Treatment in Patients with Relapsing Multiple Sclerosis (RMS)

              Author:Steinman, Lawrence   Fox, Edward   Hartung, Hans-Peter   Alvarez, Enrique   Qian, Peiqing   Wray, Sibyl   Robertson, Derrick   Selmaj, Krzysztof   Wynn, Daniel   Mok, Koby   Hsu, Yanzhi   Xu, Yihuan   Rowland, Chris   Bodhinathan, Karthik   Sportelli, Peter   Parker, Jackie   Miskin, Ha   

              Session Name:P7: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1  

              Topic:Multiple Sclerosis  

              Program Number:P7.017  

              Author Institution:Stanford Medicine, Stanford, CA  TG Therapeutics, Morrisville, NC  Heinrich Heine University Medical Faculty, Dusseldorf, Germany  University of Colorado, Aurora, CO  Swedish Medical Center, Seattle, WA  Hope Neurology, Knoxville, TN  University of South Florida, Tampa, FL  University of Warmia and Mazury, Lodz, Poland  Consultants in Neurology, Ltd., Northbrook, IL  TG Therapeutics, Oviedo, FL  TG Therapeutics, Lexington, MA  TG Therapeutics, New York, NY  UCSF, Multiple Sclerosis Center, San Francisco, CA  

              Five Years of Ublituximab in Relapsing Multiple Sclerosis: Additional Results from Open-label Extension of ULTIMATE I and II Studies

              Author:Cree, Bruce   Fox, Edward   Hartung, Hans-Peter   Alvarez, Enrique   Qian, Peiqing   Wray, Sibyl   Robertson, Derrick   Huang, Deren   Selmaj, Krzysztof   Wynn, Daniel   Mok, Koby   Hsu, Yanzhi   Xu, Yihuan   Rowland, Chris   Bodhinathan, Karthik   Sportelli, Peter   Parker, Jackie   Misk,   

              Session Name:P11: Multiple Sclerosis: Clinical and Translational Research in MS 1  

              Topic:Multiple Sclerosis  

              Program Number:P11.006  

              Author Institution:UCSF, Multiple Sclerosis Center, San Francisco, CA  TG Therapeutics, Morrisville, NC  Heinrich Heine University Medical Faculty, Dusseldorf, Germany  University of Colorado, Aurora, CO  Swedish Medical Center, Seattle, WA  Hope Neurology, Knoxville, TN  University of South Florida, Tampa, FL  Licking Memorial Hospital, Powell, OH  University of Warmia and Mazury, Lodz, Poland  Consultants in Neurology, Ltd., Northbrook, IL  TG Therapeutics, Seal Beach, CA  TG Therapeutics, Oviedo, FL  TG Therapeutics, Lexington, MA  TG Therapeutics, New York, NY  Stanford Medicine, Stanford, CA